Svastia offers a wide range of sequencing services, including RNASeq, exome or gene panels, B/T-Cell repertoire and tailored services for therapeutic antibodies. Advanced bioinformatics and biomarker analytics enable clinical decision support and patient screening for clinical trials [more..]
Cell-based drug efficacy screening, using standard or genetically modified cell lines bundled with an interactive portal to enable genetics-aided cell line selection and bioinformatic analysis [more..]
Svastia offers an independent product for therapeutic antibody development using phage- or other display platforms. Due to the sensitive nature of novel molecules, Svastia offers the flexibility of hosting the platform in-house or in private cloud environments. [more..]
For hospitals and disgnostics labs, the platform offers genetics-aided clinical decision support in oncology.
The Platform’s ready-to-use workflows could help generate clinical diagnostic reports for cancer treatment selection and relapse/response assessment.
Internal genomic data (eg, gene panels or exomes) or central sequencing labs
1200+ genetics-aided therapy options for determining positive or adverse response and the probability of relapse, prior to and during the treatment